The Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), in Moderate-to-Severe Chronic Plaque Psoriasis Primary Efficacy Objective: To assess the efficacy of tildrakizumab (SCH-900222/MK-3222) (hereafter referred to as MK-3222) compared to placebo in the treatment of moderate-to-severe chronic plaque ps...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Comparison of Pediatric Formulation (liquid) to Adult Formulation (tablets) To evaluate the comparative bioavailability between: • MK-5348 (vorapaxar) 0.2085 mg/mL oral suspension from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA; and • MK-5348 (Zontiv...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Vaginal ring dysmenorrhea feasibility trial To identify at least one dose of progestin/estrogen amongst the 4 active doses being tested, administered as a vaginal ring, that shows clinically relevant treatment efficacy in relief of primary dysm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Fosaprepitant PK/PD CINV in Pediatric Cancer Patients To determine the appropriate dosing regimen of fosaprepitant for the prevention of CINV in pediatric patients birth to 17 years of age, by assessing the pharmacokinetic and pharmacodynamic parameters,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study in patients with complicated intra-abdominal infections (infections situated within the cavity of the abdomen) conducted to assess safety, tolerability and efficacy of the study drug (MK-7655) administered together with Imipenem/Cilastatin (an antibiotic) in comparison with Imipenem/Cilastatin administered alone 1. To evaluate the efficacy of two doses of MK-7655 + imipenem/cilastatin (250 mg and 125 mg), as compared with imipenem/cilastatin alone, with respect to the clinical response assessment profile in t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude MK3475-158 : étude de phase 2, évaluant l’efficacité du pembrolizumab dans de nouvelles indications de cancers, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, os, organes… Elles représentent 90% des cancers. Les cellules cancéreuses sont initialement localisées mais peuvent se propa...

• Pays France
• Organes Tumeurs solides
• Spécialités Immunothérapie - Vaccinothérapie

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with placebo in patients with Type 2 Diabetes. Estudio para evaluar la seguridad y eficacia de la adición de un nuevo fármaco (MK-3102) comparado con placebo en pacientes con Diabetes Mellitus de tipo 2 (1) After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. (2) To assess the safety and tolerability of MK-3102. (1) Al cabo de 24 semanas, evaluar el efe...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PhII Trial of Pembrolizumab in Advanced Solid Tumors Ensayo clínico de Fase II con pembrolizumab en pacientes con tumores sólidos avanzados Objective 1: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarker-unselected subjects with any one of multiple types of advance...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy 1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A single dose study of boceprevir in children and adolescents to determine the therapeutic dose to determine weight based doses of boceprevir for children 17 to 3 years of age.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune